Takeda to acquire Ariad for $5.2bn

11-01-2017

Takeda to acquire Ariad for $5.2bn

Rawpixel.com / Shutterstock, Inc

Japan-based Takeda Pharmaceutical has acquired Ariad Pharmaceuticals, a company which develops small-molecule medicines for cancer treatments, for $5.2 billion.


Takeda, Ariad, M&A, cancer therapy, Christophe Weber, Paris Panayiotopoulos

LSIPR